{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:33:06Z","timestamp":1768786386501,"version":"3.49.0"},"reference-count":43,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"vor","delay-in-days":56,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK-2409333"],"award-info":[{"award-number":["R01-DK-2409333"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Twelve subjects with T2D and 12 with normal glucose tolerance received a euglycemic insulin clamp. Myocardial glucose uptake (MGU) and myocardial perfusion were measured with [18F]fluoro-2-deoxy-d-glucose and [15O]H2O positron emission tomography before and after 24 weeks of pioglitazone treatment. Myocardial function and transmitral early diastolic relation\/atrial contraction (E\/A) flow ratio were measured with magnetic resonance imaging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 7 \u00b1 2 and 7 \u00b1 2 mmHg, respectively (P &amp;lt; 0.05); and increased whole-body insulin-stimulated glucose uptake by 71% (3.4 \u00b1 1.3 to 5.8 \u00b1 2.1 mg\/kg \u00b7 min; P &amp;lt; 0.01) in subjects with T2D. Pioglitazone enhanced MGU by 75% (0.24 \u00b1 0.14 to 0.42 \u00b1 0.13 \u03bcmol\/min \u00b7 g; P &amp;lt; 0.01) and myocardial perfusion by 16% (0.95 \u00b1 0.16 to 1.10 \u00b1 0.25 mL\/min \u00b7 g; P &amp;lt; 0.05). Measures of diastolic function, E\/A ratio (1.04 \u00b1 0.3 to 1.25 \u00b1 0.4) and peak LV filling rate (349 \u00b1 107 to 433 \u00b1 99 mL\/min), both increased (P &amp;lt; 0.01). End-systolic volume, end-diastolic volume, peak LV ejection rate, and cardiac output trended to increase (P not significant), whereas the ejection fraction (61 \u00b1 6 to 66 \u00b1 7%) and stroke volume increased significantly (71 \u00b1 20 to 80 \u00b1 20 L\/min; both P &amp;lt; 0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-0078","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:25:29Z","timestamp":1503966329000},"page":"1530-1536","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":56,"title":["Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes"],"prefix":"10.2337","volume":"40","author":[{"given":"Geoffrey D.","family":"Clarke","sequence":"first","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"},{"name":"Department of Radiology, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Solis-Herrera","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Molina-Wilkins","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Martinez","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Merovci","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Cersosimo","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Chilton","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Texas Health Science Center, San Antonio, TX"},{"name":"South Texas Veterans Health Care System, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Iozzo","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-1651","authenticated-orcid":false,"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"},{"name":"Institute of Clinical Physiology, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-1724","authenticated-orcid":false,"given":"Muhammad","family":"Abdul-Ghani","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-6273","authenticated-orcid":false,"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[{"name":"Diabetes Division, University of Texas Health Science Center, San Antonio, TX"},{"name":"South Texas Veterans Health Care System, San Antonio, TX"},{"name":"South Texas Veterans Health Care System, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"2022031301501387300_B1","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"key":"2022031301501387300_B2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"2022031301501387300_B3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12170-011-0184-2","article-title":"Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma","volume":"5","author":"Bhuiyan","year":"2011","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"2022031301501387300_B4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0735-1097(03)00625-9","article-title":"Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus","volume":"42","author":"Diamant","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022031301501387300_B5","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","article-title":"Diabetic cardiomyopathy revisited","volume":"115","author":"Boudina","year":"2007","journal-title":"Circulation"},{"key":"2022031301501387300_B6","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","volume":"385","author":"Gilbert","year":"2015","journal-title":"Lancet"},{"key":"2022031301501387300_B7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"2022031301501387300_B8","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.108.803916","article-title":"Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus","volume":"119","author":"van der Meer","year":"2009","journal-title":"Circulation"},{"key":"2022031301501387300_B9","first-page":"1170","article-title":"Independent association of type 2 diabetes and coronary artery disease with myocardial resonance spectroscopy study","volume":"116","author":"Iozzo","year":"2002","journal-title":"Circulation"},{"key":"2022031301501387300_B10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"key":"2022031301501387300_B11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1172\/JCI114142","article-title":"Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance","volume":"84","author":"Groop","year":"1989","journal-title":"J Clin Invest"},{"key":"2022031301501387300_B12","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2009-0911","article-title":"Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus","volume":"95","author":"Bajaj","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301501387300_B13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031301501387300_B14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care"},{"key":"2022031301501387300_B15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","article-title":"Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus","volume":"50","author":"Bajaj","year":"2007","journal-title":"Diabetologia"},{"key":"2022031301501387300_B16","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.2337\/dcS13-2031","article-title":"Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301501387300_B17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"2022031301501387300_B18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2337\/db14-0694","article-title":"Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes","volume":"64","author":"Nolan","year":"2015","journal-title":"Diabetes"},{"key":"2022031301501387300_B19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1196\/annals.1302.017","article-title":"Linking gene expression to function: metabolic flexibility in the normal and diseased heart","volume":"1015","author":"Taegtmeyer","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2022031301501387300_B20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2022031301501387300_B21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2008.03.002","article-title":"Impact of peripheral arterial disease in patients with diabetes\u2014results from PROactive (PROactive 11)","volume":"202","author":"Dormandy","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022031301501387300_B22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031301501387300_B23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2022031301501387300_B24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031301501387300_B25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031301501387300_B26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031301501387300_B27","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.2337\/dc11-s233","article-title":"Safety of PPAR agonists","volume":"34","author":"Home","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031301501387300_B28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2017 executive summary","volume":"23","author":"Garber","year":"2017","journal-title":"Endocr Pract"},{"key":"2022031301501387300_B29","first-page":"S1","article-title":"Standards of medical care in diabetes\u20142017","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031301501387300_B30","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/0002-8703(93)90114-O","article-title":"Velocity-encoded cine MRI in the evaluation of left ventricular diastolic function: measurement of mitral valve and pulmonary vein flow velocities and flow volume across the mitral valve","volume":"125","author":"Hartiala","year":"1993","journal-title":"Am Heart J"},{"key":"2022031301501387300_B31","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.2337\/diabetes.51.10.3020","article-title":"Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance","volume":"51","author":"Iozzo","year":"2002","journal-title":"Diabetes"},{"key":"2022031301501387300_B32","first-page":"E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol"},{"key":"2022031301501387300_B33","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.2337\/diabetes.54.9.2787","article-title":"Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study","volume":"54","author":"Lautam\u00e4ki","year":"2005","journal-title":"Diabetes"},{"key":"2022031301501387300_B34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.metabol.2005.11.004","article-title":"Body surface area in normal-weight, overweight, and obese adults. A comparison study","volume":"55","author":"Verbraecken","year":"2006","journal-title":"Metabolism"},{"key":"2022031301501387300_B35","first-page":"1696","article-title":"Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan","volume":"39","author":"Hermansen","year":"1998","journal-title":"J Nucl Med"},{"key":"2022031301501387300_B36","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.2337\/dcS13-2003","article-title":"In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion","volume":"36","author":"Eldor","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031301501387300_B37","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1464-5491.2004.01332.x","article-title":"Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone","volume":"21","author":"H\u00e4llsten","year":"2004","journal-title":"Diabet Med"},{"key":"2022031301501387300_B38","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00005344-200112000-00008","article-title":"Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat","volume":"38","author":"Tsuji","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022031301501387300_B39","doi-asserted-by":"crossref","first-page":"703735","DOI":"10.1155\/2010\/703735","article-title":"Regulation of EnaC-mediated sodium reabsorption by peroxisome proliferator-activated receptors","volume":"2010","author":"Pavlov","year":"2010","journal-title":"PPAR Res"},{"key":"2022031301501387300_B40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat Med"},{"key":"2022031301501387300_B41","first-page":"401","article-title":"Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study","volume":"65","author":"Ordu","year":"2010","journal-title":"Acta Cardiol"},{"key":"2022031301501387300_B42","author":"Derosa"},{"key":"2022031301501387300_B43","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2337\/diabetes.52.8.1943","article-title":"Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients","volume":"52","author":"Miyazaki","year":"2003","journal-title":"Diabetes"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc17-0078","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/11\/1530\/551918\/dc170078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/40\/11\/1530\/551918\/dc170078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:52:33Z","timestamp":1647150753000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/40\/11\/1530\/36931\/Pioglitazone-Improves-Left-Ventricular-Diastolic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,8,28]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-0078","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,28]]}}}